Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Amlodipine
Drug ID BADD_D00121
Description Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers [A175327]. Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure [A175321]. The option for single daily dosing of amlodipine is an attractive feature of this drug [FDA label].
Indications and Usage For the treatment of hypertension and chronic stable angina.
Marketing Status Prescription; Discontinued
ATC Code C08CA01
DrugBank ID DB00381
KEGG ID D07450
MeSH ID D017311
PubChem ID 2162
TTD Drug ID D08JIV
NDC Product Code 52652-5001; 46287-035
Synonyms Amlodipine | Amlodipine, (+-)-Isomer | Amlodipine Besylate | Amlodipine, (+-)-Isomer, Maleate (1:1) | Amlodipine, (S)-Isomer, Maleate (1:1) | Amlodis | Astudal | Norvasc | Istin | Amlor | Amlodipine Maleate | Amlodipine Maleate (1:1) | Amlodipine, (R)-Isomer
Chemical Information
Molecular Formula C20H25ClN2O5
CAS Registry Number 88150-42-9
SMILES CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Erectile dysfunction21.03.01.007; 19.08.04.0010.000061%
Renal function test abnormal13.13.01.0120.000031%Not Available
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Parkinson's disease17.01.05.0100.000032%Not Available
Blood disorder01.05.01.004--Not Available
Disease progression08.01.03.038--
Drug intolerance08.06.01.0130.000246%Not Available
Psychotic disorder19.03.01.002--
Hyperlipidaemia14.08.03.0010.000046%
Renal impairment20.01.03.0100.000246%Not Available
Unevaluable event08.01.03.051--Not Available
Chronic kidney disease20.01.03.0170.000056%
Bone marrow failure01.03.03.005--
Pharyngeal inflammation22.04.05.0080.000046%
Bronchial hyperreactivity22.03.01.016--Not Available
Brain injury19.07.03.007; 17.11.01.0030.000008%Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.0040.000061%
Acute kidney injury20.01.03.0160.000445%
Foetal growth restriction18.03.01.0020.000031%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.000092%Not Available
Sinus node dysfunction02.03.03.0170.000046%
Multiple organ dysfunction syndrome08.01.03.0570.000024%
Liver function test increased13.03.01.044--Not Available
Depersonalisation/derealisation disorder19.14.01.004--Not Available
Biliary cirrhosis primary10.04.09.003; 09.01.04.0070.000031%Not Available
Cardiac failure chronic02.05.01.0090.000008%Not Available
Cerebellar haemorrhage24.07.04.023; 17.08.01.0460.000008%Not Available
Cerebral artery thrombosis24.01.04.008; 17.08.01.0260.000031%Not Available
Coeliac disease14.02.01.007; 10.04.04.012; 07.17.01.0080.000031%Not Available
The 16th Page    First    Pre   16 17    Next   Last    Total 17 Pages